Alerta

一种基于三(2-氨基乙基)胺的可电离脂质、脂质纳米颗粒及其制备方法与应用

Resumen de: CN121673192A

本发明属于生物医药技术领域，涉及一种基于三(2‑氨基乙基)胺的可电离脂质、脂质纳米颗粒及其制备方法与应用。其化学结构如式I所示，其中，R1、R2分别独立地选自取代或未取代的C8‑C14烷基、取代或未取代的C8‑C14烯基、取代或未取代的C8‑C14炔基。本发明提供的基于三(2‑氨基乙基)胺的可电离脂质形成脂质纳米颗粒具有可生物降解性和转染效率高的优点。

小分子药物saEml1及其在脊髓损伤修复中的应用

Resumen de: CN121668182A

本发明公开了小分子药物saEml1及其在脊髓损伤修复中的应用。本发明将saEml1封装于PLGA‑NPs中，再把纳米粒均匀分散于可光交联的GelMA水凝胶内，制成可注射复合体系。将该凝胶纳米粒复合物填充于脊髓损伤腔，利用GelMA三维支架实现saEml1局部滞留，并借助PLGA‑NPs的降解特性使saEml1在病灶局部持续释放。该体系兼具机械支撑+药物缓释双重功能，可在损伤微环境内维持saEml1有效浓度，持续激活Eml1，从而促进轴突再生，显著提高治疗效果。

一种金属多酚纳米酶及其制备方法和应用

Resumen de: CN121668192A

本发明涉及一种金属多酚纳米酶，所述金属多酚纳米酶包括核和壳，所述核包括铈、单宁酸和白藜芦醇，所述壳包括杂化细胞膜，所述壳包裹于核的表面。所述金属多酚纳米酶的制备方法包括以下步骤：金属多酚纳米颗粒的制备；杂化细胞膜的提取和核‑壳的一体化。本发明的金属多酚纳米酶具有催化活性与选择性的显著提升、靶向能力与病灶富集的改进以及可控释放与安全性。

一种靶向细菌负载上转换纳米颗粒的双展示噬菌体复合体及其制备方法与应用

Resumen de: CN121668309A

本发明涉及一种靶向细菌负载上转换纳米颗粒的双展示噬菌体复合体及其制备方法与应用，属于生物医药和纳米技术交叉领域。本发明靶向细菌负载上转换纳米颗粒的双展示噬菌体复合体包括上转换纳米颗粒和双展示靶向肽的噬菌体，双展示靶向肽的噬菌体上修饰有能够与细菌靶向结合和能够与上转换纳米颗粒靶向结合的靶向肽，上转换纳米颗粒由内至外修饰有光敏剂、红细胞膜和光热剂；上转换纳米颗粒用于在照射光下产生发射光，光敏剂用于在发射光下产生活性氧，光热剂用于在所述照射光下产热和成像。本发明中的复合体能够特异性识别细菌感染病灶，并实现近红外光激发的发光成像、光动力治疗与光热治疗的协同杀菌作用。

一种纳米粒交联水凝胶及其应用

Resumen de: CN121668090A

本发明公开了一种纳米粒交联水凝胶及其应用，该纳米粒交联水凝胶由端基功能化的纳米粒和侧链功能化修饰的亲水性高分子材料制成，由于硫醇基团和不饱和双键基团可通过迈克尔加成反应进行连接，因此选择硫醇基团和不饱和双键基团形成纳米粒和亲水性高分子材料的连接键从而实现水凝胶成型。本发明以纳米粒为交联剂的水凝胶递送系统，通过纳米粒与水凝胶的双重装载策略，实现了多种药物的装载与递送。

コロナウイルスワクチン

Resumen de: ZA202406805B

The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.

脂質ナノ粒子製剤における使用のための脂質

Resumen de: US2025084029A1

Compounds are provided having the following structure:or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R3, L1, L2, G1, G2 and G3 are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.

抗トランスフェリン受容体抗体及びその使用

Resumen de: JOP20250221A1

The present disclosure provides anti-transferrin receptor antibodies, compositions comprising the same and methods of use for delivery of cargo to brain tissue. This disclosure also provides polynucleotides and vectors encoding the anti-transferrin receptor antibodies and cells comprising the same, methods of making the antibodies, and molecules comprising the antibodies.

ｍＲＮＡのデリバリーシステム

Resumen de: JP2026047994A

【課題】 mRNAのデリバリーに適したナノ粒子を提供すること。【解決手段】カチオン性高分子とアニオン性多糖とを含む、mRNAデリバリーのためのナノ粒子であって、カチオン性高分子がキトサン又はその塩である前記ナノ粒子。前記ナノ粒子とmRNAとを含む、組成物。【選択図】図６

抗ウイルスプロドラッグの製剤

Resumen de: MX2025010834A

Disclosed herein, in part, are pharmaceutical compositions comprising a prodrug of an antiviral agent and methods of using the same in the treatment of viral infections.

一种积雪草苷和小檗碱共载PLGA纳米粒的制备方法

Resumen de: CN121648075A

本发明公开了一种积雪草苷和小檗碱共载PLGA纳米粒的制备方法，包括以下步骤，称取积雪草苷、小檗碱、PLGA，放置于EP管中，加入甲醇和乙醇混合体系，溶解完全得到溶液一；配置体积分数为1％的PVA溶液；将上述溶液一进行磁力搅拌，室温下搅拌，搅拌频率为120r/min，得到溶液二；用注射器吸取PVA溶液缓慢滴入上述步骤3的溶液二中，得到溶液三；将溶液三搅拌后，放在冰浴中超声；超声结束后，用超滤管纯化除去游离药物以及甲醇和乙醇溶液，获得积雪草苷和小檗碱共载PLGA纳米粒；本发明有利于提高原料药物的可溶性和稳定性，进而提高Asi和Ber的共同包封率。

一种仿生细胞膜修饰光敏剂的制备及其应用

Resumen de: CN121652172A

本发明公开一种仿生细胞膜修饰光敏剂的制备及其应用。本发明采用肿瘤细胞膜仿生伪装技术，通过反复过膜挤压或超声将肿瘤细胞膜包覆在光敏剂纳米粒表面，制得一种包载光敏剂的肿瘤细胞膜仿生纳米粒，其制备工艺简单、成本低、不需要复杂的合成过程。本发明所公开的仿生纳米粒具有同源靶向和免疫逃逸的功能，并能实现近红外二区成像。此外该仿生纳米粒可以通过光热和光动力效应杀伤肿瘤细胞，具有疗效好、毒副作用低的优势。

黄花蒿细胞来源的外泌体纳米囊泡及其内含物过氧化物酶A0A2U1N9S9在制备抗结直肠癌药物中的应用

Resumen de: CN121648271A

本发明公开了黄花蒿细胞来源的外泌体纳米囊泡及其内含物过氧化物酶A0A2U1N9S9在制备抗结直肠癌药物中的应用。经抗CRC活性分析，结果表明黄花蒿细胞来源的外泌体纳米囊泡对DLD‑1和HCT116细胞株的生长具有抑制作用，并基于蛋白质组学技术的差异性分析首次创新性揭示了ACDENVs抑制DLD‑1和HCT116细胞株生长的活性物质基础——过氧化物酶A0A2U1N9S9，为抗结直肠癌药物研究提供了新的研究思路和理论依据。

可离子化脂质及其应用

Resumen de: AU2024307443A1

The present invention provides an ionizable lipid and a drug delivery system comprising the ionizable lipid. Specifically, the present invention provides an ionizable lipid having a structure of formula (I), or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof. Lipid nanoparticles constructed by using the ionizable lipid can realize safe and efficient delivery of nucleic acid drugs, small molecule drugs, peptide drugs and protein drugs.

一种仿生纳米平台及其制备方法与应用

Resumen de: CN121648290A

本发明具体公开了一种仿生纳米平台及其制备方法与应用，涉及生物医药技术领域。本发明仿生纳米平台通过构建Ni与LDH的肖特基异质结结构，实现了超声能量到化学能（CO释放）的高效转换。此外，通过肿瘤细胞膜包覆赋予其“同源识别”特性，使其能够主动靶向脑胶质瘤并穿越BBB，实现精准递送与深部肿瘤富集。

一种NIR-Ⅱ多模态光诊疗剂及其制备方法和应用

Resumen de: CN121648318A

本发明公开了一种具有A‑D‑A型兼具多模态成像引导与光动力‑光热协同治疗功能的NIR‑Ⅱ多模态光诊疗剂及其制备方法和应用，其包括结构式如式I所示的化合物，或其药学上可接受的盐、其溶剂化物和其互变异构体。本发明的NIR‑Ⅱ多模态光诊疗材料，结合多模态成像引导和光热‑光动力效应，可以克服现有技术中的诸多局限性，实现对肿瘤、炎症等疾病的高效诊断和治疗，进而推动多模态诊疗技术的发展。

一种金属-多胺纳米复合物及其制备方法与应用

Resumen de: CN121648081A

本发明属于纳米生物材料与肿瘤放射免疫治疗领域，具体涉及一种金属‑多胺纳米复合物及其制备方法与应用。所述纳米复合物是由二价锰离子与亚精胺在油酸介导下通过配位形成疏水核心，并采用DSPE‑PEG进行表面包覆构建而成的核壳结构纳米颗粒。通过二价锰离子与亚精胺的配位组装及DSPE‑PEG表面修饰，实现同步激活cGAS‑STING通路以促进DCs成熟，并增强CD8+ T细胞线粒体脂肪酸氧化功能，增强放疗诱导的抗肿瘤效果。

ヒト化モノクローナル終末糖化産物抗体

Resumen de: JP2024010037A

To provide a humanized monoclonal advanced glycation end-product antibody for therapeutic applications.SOLUTION: A humanized monoclonal antibody that binds to an advanced glycation end-product-modified protein or peptide on a cell comprises a heavy chain and a light chain. The antibody binds a carboxymethyllysine-modified protein or peptide. A composition comprises a humanized monoclonal antibody that binds to an advanced glycation end-product-modified protein or peptide on a cell and a pharmaceutically acceptable carrier.SELECTED DRAWING: None

췌장 효소를 포함하는 관능화된 생촉매 조성물

Resumen de: AU2024288835A1

The present invention relates to a composition comprising a solid carrier, a lipase or a fragment thereof immobilized on the surface of the solid carrier wherein the lipase or a fragment thereof is in the open conformation, a protease or a fragment thereof immobilized on the surface of the solid carrier, an amylase or a fragment thereof immobilized on the surface of the solid carrier, an agent which interacts with the lid domain of the lipase or a fragment thereof, a protective layer to protect the lipase or a fragment thereof, the protease or a fragment thereof and the amylase or a fragment thereof by embedding the lipase or a fragment thereof, the protease or a fragment thereof and the amylase or a fragment thereof, and a functional constituent immobilized on the surface of the protective layer, wherein the functional constituent immobilized on the surface of the protective layer is a polymer comprising repeat units wherein each repeat unit comprises at least one amino group and/or at least one thiol group.

관능화된 이당류 분해효소 조성물

Resumen de: AU2024289812A1

The present invention relates to a composition comprising a solid carrier, a protein disaccharidase or a fragment thereof immobilized on the surface of the solid carrier, a protective layer to protect the protein disaccharidase or a fragment thereof by embedding the protein disaccharidase or a fragment thereof, and a functional constituent immobilized on the surface of the protective layer, wherein the functional constituent immobilized on the surface of the protective layer is a polymer comprising repeat units wherein each repeat unit comprises at least one amino group and/or at least one thiol group. The present invention also relates to methods of producing said composition.

イオン化可能な脂質分子およびその調製方法と使用

Resumen de: AU2024231082A1

An ionizable lipid molecule, a preparation method therefor and a use thereof. Specifically, provided are a compound represented by formula I, and a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug or solvate thereof. The definition of each group in the formula is as described in the description. Also provided is a lipid nanoparticle, containing the ionizable lipid compound represented by formula (I). Further provided are a composition and a related use. The compound of formula I can be used to prepare the lipid nanoparticle for delivering a nucleic acid therapeutic agent or an active agent in vivo and in vitro.

薬学的使用のためのＲＮＡ製剤

Resumen de: CN120712350A

The present disclosure relates to an RNA comprising one or more miRNA binding sequences, wherein the one or more miRNA binding sequences bind to a miRNA present in a cell in which expression of the RNA is not desired. After administration, in particular after intramuscular or intravenous administration, the RNA is delivered to a cell such that the polypeptide encoded by the RNA is expressed in certain cells while inhibiting expression in other cells. In some embodiments, such cells comprise endothelial cells. The RNA compositions described herein allow for expression of a pharmaceutically active peptide or polypeptide in a subject by the RNA while reducing or avoiding the risk of undesirable effects caused by expression of the pharmaceutically active peptide or polypeptide in certain cells or tissues.

遺伝子送達ビヒクルの医薬製剤

Resumen de: CN120603600A

The present invention relates to formulations comprising miRNAs having improved stability for use in the treatment of diseases, including neurodegenerative diseases, such as spinal cerebellar ataxia type 3.5.

治療用組成物及び治療方法

Resumen de: CN120603580A

Therapeutic compositions and methods. Disclosed is a composition comprising: a particle comprising hydrolysable doped silicon; one or more lipids; and an active pharmaceutical ingredient (API). Also disclosed are related products, methods and uses thereof.

肺癌用新規腫瘍抗原およびその使用

Nº publicación: JP2026508854A 13/03/2026

Solicitante:

ウニヴェルシテドモントリオール

Resumen de: CN120858107A

Lung cancer is still the main cause of cancer-related death in the world. Although the introduction of an immune checkpoint inhibitor (ICI) makes a significant progress in lung cancer treatment, disease prognosis is still low, and a substantial portion of patients are not responsive to such therapy. The cancer vaccine can potentially provide a complementary approach to enhance anti-tumor immunity and act synergistically with ICI. Described herein are novel tumor antigens common to most lung tumor cells. Several tumor antigens described herein are derived from aberrantly expressed, non-mutated genomic sequences, such as intra-gene sequences and intergene sequences, which are not expressed in normal tissue. Nucleic acids, compositions, cells and vaccines derived from these tumor antigens are described. The use of the tumor antigens, nucleic acids, compositions, cells and vaccines for the treatment of lung cancer is also described.